Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
The event further establishes LALPINA CBD’s connection to professional athletes as the Company looks to penetrate the $30 billion US fitness market PLAYA VISTA, Apr 25, 2019 – American Premium Water Corporation(OTC: HIPH) announces that […]
Upon closing of pending acquisitions, the Company will operate a total of 14 dispensaries within Colorado- The acquisitions are part of MMT’s strategy aimed at creating an integrated operation, to include proven and profitable cultivation, […]
FSD Pharma Announces Strategic Investment in Huge Shops – Huge Shops forms alliance with Coffee Time’s parent company Chairman’s Brands to establish retail distribution network – TORONTO—FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
